Trial Profile
Phase II, open label clinical study to investigate anti-tumour effect and tolerability of the PARP inhibitor 2X-121 in patients with metastatic breast cancer selected by the 2X-121 DRP.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Stenoparib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Allarity Therapeutics
- 28 Mar 2023 According to Allarity Therapeutics media release, company anticipates that it will have sufficient DRP-positive patient enrollment to support an interim data readout from this study in late 2023.
- 28 Mar 2023 Trial protocol was amended that will lower IXEMPRA-DRP companion diagnostic cut-off score, for enrollment, from 67% to 33%.
- 28 Mar 2023 According to Allarity Therapeutics media release, company is expanding its CRO partnerships and has implemented a trial protocol amendment.